

Joel Guigay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5102781/publications.pdf>

Version: 2024-02-01

69
papers

7,546
citations

230014

27
h-index

124990

64
g-index

78
all docs

78
docs citations

78
times ranked

10188
citing authors

#	ARTICLE	IF	CITATIONS
1	Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: <sc>DIRECT</sc>. Cancer Reports, 2022, 5, e1467.	0.6	4
2	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist, 2022, 27, e194-e198.	1.9	18
3	Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?. Current Opinion in Oncology, 2022, 34, 196-203.	1.1	3
4	Editorial: Head and neck squamous cell cancer: ways to optimize the treatment and improve the outcomes. Current Opinion in Oncology, 2022, 34, 169.	1.1	0
5	Editorial: Head and neck cancers: recent pathological approaches and new therapeutic guidelines for sino-nasal, thyroid and squamous cell carcinomas. Current Opinion in Oncology, 2021, 33, 159.	1.1	0
6	Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes. Current Opinion in Oncology, 2021, 33, 160-167.	1.1	9
7	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC) Tj ETQq1 1 0,784314 r9BT /Overl 463-475.	5.1	95
8	Unresolved questions regarding the promise of the TPEx regimen â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e228-e229.	5.1	3
9	Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Investigational New Drugs, 2021, 39, 1641-1648.	1.2	9
10	Phase II, Randomized Study of Spartalizumab (PDR001), an Antiâ€“PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. Clinical Cancer Research, 2021, 27, 6413-6423.	3.2	37
11	Efficacy and safety of immune checkpoint inhibitors in elderly patients (â‰¥70 years) with squamous cell carcinoma of the head and neck. European Journal of Cancer, 2021, 157, 190-197.	1.3	6
12	Tumors: Oto-Rhino-Laryngology. , 2021, , 1-12.		0
13	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
14	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. European Journal of Cancer, 2021, 158, 17-26.	1.3	33
15	Tumors: Oto-Rhino-Laryngology. , 2021, , 5279-5291.		0
16	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bulletin Du Cancer, 2020, 107, 946-958.	0.6	15
17	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Scientific Reports, 2020, 10, 3565.	1.6	29
18	Editorial: Head and neck cancers: new perspectives in prevention and treatment. Current Opinion in Oncology, 2020, 32, 177.	1.1	0

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study. <i>Clinical Chemistry</i> , 2019, 65, 1267-1275.	1.5	38
20	The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions. <i>Frontiers in Oncology</i> , 2019, 9, 668.	1.3	33
21	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. <i>Oral Oncology</i> , 2019, 96, 7-14.	0.8	45
22	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	3.2	115
23	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	2.0	64
24	Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2019, 121, 123-129.	1.3	115
25	Approach to the Patient with Recurrent/Metastatic Disease. <i>Current Treatment Options in Oncology</i> , 2019, 20, 65.	1.3	8
26	Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2531-2539.	0.8	13
27	Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1357-1366.	1.1	19
28	The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. <i>Cancers</i> , 2019, 11, 250.	1.7	2
29	Molecular genetics of head and neck squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2019, 31, 131-137.	1.1	30
30	Treatment of inoperable elderly head and neck cancer patients. <i>Current Opinion in Oncology</i> , 2019, 31, 152-159.	1.1	11
31	Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck. <i>Current Opinion in Oncology</i> , 2019, 31, 146-151.	1.1	25
32	Things are changing for head and neck squamous cell carcinomas. <i>Current Opinion in Oncology</i> , 2019, 31, 121.	1.1	2
33	TPEXtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6002-6002.	0.8	58
34	Efficacy and safety of immune checkpoint inhibitors in elderly patients (>=70 years) with squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6035-6035.	0.8	2
35	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. <i>Oral Oncology</i> , 2018, 81, 45-51.	0.8	589
36	Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018, 80, 104-107.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Jointed French-Italian Retrospective Multicenter Study. <i>Neuroendocrinology</i> , 2018, 106, 264-273.	1.2	14
38	Predicting early death in older adults with cancer. <i>European Journal of Cancer</i> , 2018, 100, 65-74.	1.3	46
39	CheckMate 141: 1â€Year Update and Subgroup Analysis of Nivolumab as Firstâ€Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. <i>Oncologist</i> , 2018, 23, 1079-1082.	1.9	70
40	NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 681-685.	1.1	8
41	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	5.1	325
42	Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. <i>Oncotarget</i> , 2017, 8, 51830-51839.	0.8	2
43	Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3299-3306.	0.8	17
44	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
45	Further evaluations of nivolumab (nivo) versus investigatorâ€™s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	0.8	32
46	Effect of Nasopharyngeal Carcinoma-Derived Exosomes on Human Regulatory T Cells. <i>Journal of the National Cancer Institute</i> , 2015, 107, 363.	3.0	167
47	Prise en charge globale des carcinomes Ã©pidermoÃ©des de la tÃªte et du cou (CETEC) en 2015. <i>Oncologie</i> , 2015, 17, 215-219.	0.2	1
48	Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. <i>Annals of Oncology</i> , 2015, 26, 1941-1947.	0.6	113
49	Integrating genomics in head and neck cancer treatment: Promises and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 397-406.	2.0	29
50	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 583-594.	5.1	358
51	Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. <i>Anti-Cancer Drugs</i> , 2014, 25, 1220-1226.	0.7	4
52	Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 823-831.	1.0	44
53	Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS6099-TPS6099.	0.8	11
54	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes. <i>Oral Oncology</i> , 2013, 49, 482-491.	0.8	41

#	ARTICLE	IF	CITATIONS
55	Specific detection of Epstein-Barr virus microRNAs in plasma samples from nasopharyngeal carcinoma patients: Correlation with tumor mass assessed by MRI.. Journal of Clinical Oncology, 2013, 31, 6079-6079.	0.8	0
56	Use of gene expression signature to discriminate oropharyngeal cancers according to HPV16 status.. Journal of Clinical Oncology, 2013, 31, 6055-6055.	0.8	0
57	Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma. Journal of Thoracic Oncology, 2012, 7, 1179-1183.	0.5	23
58	Intervention in gastro-enteropancreatic neuroendocrine tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 855-865.	1.0	16
59	Cetuximab, docetaxel, and cisplatin (TPEX) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.. Journal of Clinical Oncology, 2012, 30, 5505-5505.	0.8	14
60	Chromogranin a Measurement in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: Screening for False Positives and a Prospective Follow-Up Study. International Journal of Biological Markers, 2011, 26, 94-101.	0.7	38
61	Performance of 18Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (â‰¥10%) Well-Differentiated Endocrine Carcinoma Staging. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 665-671.	1.8	93
62	Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01. Journal of Clinical Oncology, 2010, 28, 21-28.	0.8	172
63	Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocrine-Related Cancer, 2009, 16, 585-597.	1.6	105
64	Blood diffusion and Th1-suppressive effects of galectin-9â€“containing exosomes released by Epstein-Barr virusâ€“infected nasopharyngeal carcinoma cells. Blood, 2009, 113, 1957-1966.	0.6	350
65	Advances in nasopharyngeal carcinoma. Current Opinion in Oncology, 2008, 20, 264-269.	1.1	63
66	P1-123: Response of atypical pulmonary carcinoid tumors to chemotherapy. A retrospective study of 37 patients.. Journal of Thoracic Oncology, 2007, 2, S599.	0.5	4
67	Anti-Î±-enolase antibodies in cancer-associated retinopathy with small cell carcinoma of the lung. American Journal of Ophthalmology, 2005, 139, 746-747.	1.7	54
68	Bronchoscopy with the Vision Sciences BF100 Disposable-Sheath Device: French Experience after 328 Procedures. Respiration, 2004, 71, 174-177.	1.2	10
69	Ga-67 Citrate Imaging of a Primary Thymic Seminoma. Clinical Nuclear Medicine, 1998, 23, 471-473.	0.7	0